Clinical trials: Adalimumab
Rheumatoid Arthritis
Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab
A Phase 2b, open-label extension (OLE) study in rheumatoid arthritis (RA) patients designed to collect long-term safety, tolerability, efficacy, and immunogenicity data of the proposed new adalimumab formulation.
- Trial name
- NCT01752855
- Testing
- New formulation adalimumab
- Where
- 20 sites in United States, Belgium and 5 more
- Volunteers
- 88 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with…
- Trial name
- NCT04230213
- Testing
- PF-06410293, adalimumab
- Where
- 72 sites in United States, Bosnia and Herzegovina and 8 more
- Volunteers
- 455 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients
The purpose of the study is to compare the long-term safety, effectiveness and immunogenicity of FKB327 in comparison to Humira® in rheumatoid arthritis patients who have completed study FKB327-002 and have inadequate disease…
- Trial name
- ARABESC-OLE (NCT02405780)
- Testing
- FKB327, Humira®
- Where
- 92 sites in United States, Canada and 9 more
- Volunteers
- 645 people
- Sponsor
- Fujifilm Kyowa Kirin Biologics Co., Ltd.
RHEUMATOID ARTHRITIS
Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient
Compare the efficacy of adding small doses of prednisolone (10 mg) daily to the efficacy of adding one of the available anti TNF in the treatment of methotrexate inadequate responder rheumatoid arthritis patient.
- Trial name
- NCT01724268
- Testing
- Pred + Meth, Anti TNF + Meth
- Where
- Qatar
- Volunteers
- 80 people
- Sponsor
- Hamad Medical Corporation
Rheumatoid Arthritis
A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety
A study in Rheumatoid Arthritis (RA) patients to evaluate two formulations of adalimumab for pharmacodynamics, pharmacokinetics, and safety.
- Trial name
- NCT01712178
- Testing
- Adalimumab, current formulation, Adalimumab, new formulation
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 100 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Arthritis, Psoriatic
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying anti-Rheumatic Drug Therapy
- Trial name
- NCT00646178
- Testing
- adalimumab
- Volunteers
- 102 people
- Sponsor
- Abbott
Phase 1
PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)
This study has been designed as a multicentre, randomised, open label study of AVT02 in healthy adult subjects. The study will assess the PK, safety and tolerability of AVT02 in Pre-Filled Syringe compared to AVT02 in…
- Trial name
- NCT03983876
- Testing
- Adalimumab
- Where
- 2 sites in New Zealand
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Alvotech Swiss AG
Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.
- Trial name
- SPIRIT-H2H (NCT03151551)
- Testing
- Ixekizumab, Adalimumab
- Where
- 131 sites in Argentina, Australia and 20 more
- Volunteers
- 566 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis
A study to evaluate the safety and efficacy of adalimumab in Chinese subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT01646073
- Testing
- Adalimumab
- Where
- 16 sites in China
- Volunteers
- 425 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ankylosing Spondylitis
Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice
The purpose of this study was to assess the proportion of AS patients achieving treatment response to adalimumab therapy.
- Trial name
- IDEA (NCT01754727)
- Volunteers
- 452 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis
To evaluate the safety profile, the effectiveness and the economic impact of adalimumab when used for the treatment of subjects with active plaque psoriasis who have not adequately responded to prior psoriasis therapy.
- Trial name
- PRIDE (NCT00513370)
- Testing
- Humira (adalimumab)
- Where
- 27 sites in Canada
- Volunteers
- 203 people
- Sponsor
- Abbott
Psoriasis
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- CHAMPION (NCT00235820)
- Testing
- adalimumab, MTX
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
This randomized, blinded, parallel arm study evaluated the efficacy and safety of tocilizumab (RoActemra/Actemra) versus adalimumab as monotherapy in patients with rheumatoid arthritis who are intolerant of methotrexate or where…
- Trial name
- NCT01119859
- Testing
- Tocilizumab, Adalimumab
- Where
- 82 sites in United States, Australia and 13 more
- Volunteers
- 326 people
- Sponsor
- Hoffmann-La Roche
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing…
- Trial name
- NCT04527380
- Testing
- Ixekizumab, Adalimumab
- Where
- 43 sites in Argentina, Belgium and 10 more
- Volunteers
- 101 people
- Sponsor
- Eli Lilly and Company
Crohn's Disease
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.
- Trial name
- NCT02065570
- Testing
- Adalimumab
- Where
- 143 sites in United States, Austria and 18 more
- Volunteers
- 514 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Quality of Life Study With Adalimumab in Rheumatoid Arthritis
The purpose of the study is to evaluate the ability of adalimumab combined with methotrexate to improve the quality of life in patients with active RA.
- Trial name
- NCT00234936
- Testing
- Adalimumab, Methotrexate
- Volunteers
- 200 people
- Sponsor
- Abbott
Hidradenitis Suppurativa
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- LYRA (NCT04988308)
- Testing
- Bermekimab, Adalimumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Janssen Research & Development, LLC
Moderate to Severe Crohn's Disease
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
The purpose of this study is to evaluate the rapidity of onset of clinical response to adalimumab therapy in patients with luminal Crohn's disease.
- Trial name
- RAPIDA (NCT02148718)
- Testing
- adalimumab
- Volunteers
- 100 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab
The study is designed as a prospective, observational study to assess the effect of adalimumab on health-related quality of life (QoL) and work productivity in patients with rheumatoid arthritis (RA) in Korea.
- Trial name
- ROCKA (NCT02627924)
- Volunteers
- 91 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Observation of safety, tolerability and effectiveness of adalimumab (Humira) therapy in a large patient collective under everyday clinical conditions over a 5-year period.
- Trial name
- NCT01078090
- Where
- 370 sites in Germany
- Volunteers
- 5,745 people
- Sponsor
- AbbVie (prior sponsor, Abbott)